Apollo Therapeutics (Group)

https://www.apollotherapeutics.com

Apollo Therapeutics (“Apollo”) is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines. The portfolio-model is built around a centralized management team of capital allocators and functional leaders with deep expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated and seasoned asset leader. Assets are housed in separate wholly owned subsidiary companies, a “hub-and-spoke” approach. The advantages of this model, which incorporates best practices from big pharma and venture capital, are (1) enhanced focus at the individual asset level; (2) access to centralized expertise and scale-up capabilities, providing operational efficiencies; (3) attraction of the best talent into both centralized management team and asset leadership positions; (4) flexibility in both capital financing and routes to liquidity, and (5) risk mitigation through a diversified portfolio with uncorrelated risk, attracting a wider investor base. The Company has a scalable R&D platform for the evergreen discovery and development of new medicines. This is enabled by an unprecedented level of access to five of the world’s leading universities and research institutes. Program selection is agnostic to indication and is primarily driven by the quality of the science and the potential to transform the standard of care in major commercial markets. The Company is focused on establishing evidence of causal human biology for its therapeutic targets using human genetics and genetic epidemiology. Backed by leading specialist health care investors, Apollo has operations in Cambridge, U.K., and Boston and Chicago, U.S. Apollo has raised a total of over $450m since its inception. *

	Start	2016-01-25 established jv
	Industry	venture capital
	Industry 2	translational medicine / translational research
	Person	Mason, Richard (Apollo Therapeutics 202401 CEO formerly JnJ Innovation Centre London +XO1 + BTG + 4-Antibody)
	Person 2	Tomlinson, Ian (MRC + Domantis)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	22 Station Road 3rd Floor
	City	CB1 2JD Cambridge, Cambridgeshire
		Address record changed: 2024-01-28

Basic data	Employees	n. a.
	Currency	GBP
	Annual sales	40,000,000 (assets, dedicated 2016-01-26)

		* Document for »About Section«: Apollo Therapeutics. (1/2/24). "Press Release: Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million". Cambridge & Boston, MA.

		Record changed: 2024-01-29